{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:51:49Z","timestamp":1776873109870,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,25]]},"DOI":"10.7759\/cureus.24453","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T08:00:07Z","timestamp":1650873607000},"source":"Crossref","is-referenced-by-count":6,"title":["Role of Faropenem in Treatment of Pediatric Infections: The Current State of Knowledge"],"prefix":"10.7759","author":[{"given":"Sumitha","family":"Nayak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Birla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cppeds.2011.06.001","article-title":"Common childhood bacterial infections","volume":"41","author":"Alter SJ","year":"2011","unstructured":"Alter SJ, Vidwan NK, Sobande PO, Omoloja A, Bennett JS. Common childhood bacterial infections. Curr Probl Pediatr Adolesc Health Care. 2011, 41:256-83. 10.1016\/j.cppeds.2011.06.001","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/850674","article-title":"Common periodontal diseases of children and adolescents","volume":"2014","author":"Al-Ghutaimel H","year":"2014","unstructured":"Al-Ghutaimel H, Riba H, Al-Kahtani S, Al-Duhaimi S. Common periodontal diseases of children and adolescents. Int J Dent. 2014, 2014:1-7. 10.1155\/2014\/850674","journal-title":"Int J Dent"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.18683\/germs.2021.1293","article-title":"Urinary tract infections in children: clinical and antimicrobial resistance data from Bucharest area, Romania","volume":"11","author":"Miron VD","year":"2021","unstructured":"Miron VD, Filimon C, Cabel T, Mih\u0103escu RI, Bar G, Leu D, Craiu M. Urinary tract infections in children: clinical and antimicrobial resistance data from Bucharest area, Romania. Germs. 2021, 11:583-91. 10.18683\/germs.2021.1293","journal-title":"Germs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.1.35","article-title":"The in-vitro activity of faropenem, a novel oral penem","volume":"39","author":"Woodcock JM","year":"1997","unstructured":"Woodcock JM, Andrews JM, Brenwald NP, Ashby JP, Wise R. The in-vitro activity of faropenem, a novel oral penem. J Antimicrob Chemother. 1997, 39:35-43. 10.1093\/jac\/39.1.35","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace KM","year":"2011","unstructured":"Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011, 55:4943-60. 10.1128\/AAC.00296-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/IM9.0000000000000015","article-title":"Faropenem susceptibility of multidrug-resistant clinical isolates from Zhejiang Province, China","volume":"2","author":"Feng XW","year":"2020","unstructured":"Feng XW, Shao JD, Ji ZK, et al.. Faropenem susceptibility of multidrug-resistant clinical isolates from Zhejiang Province, China. Infect Microbes Dis. 2020, 2:26-9. 10.1097\/IM9.0000000000000015","journal-title":"Infect Microbes Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G232","article-title":"Faropenem medoxomil","volume":"42","author":"Gettig JP","year":"2008","unstructured":"Gettig JP, Crank CW, Philbrick AH. Faropenem medoxomil. Ann Pharmacother. 2008, 42:80-90. 10.1345\/aph.1G232","journal-title":"Ann Pharmacother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00049-07","article-title":"Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel","volume":"51","author":"Stone KC","year":"2007","unstructured":"Stone KC, Dagan R, Arguedas A, et al.. Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel. Antimicrob Agents Chemother. 2007, 51:2230-5. 10.1128\/AAC.00049-07","journal-title":"Antimicrob Agents Chemother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000070616","article-title":"The art of fusion: from penams and cephems to penems","volume":"49","author":"Dalhoff A","year":"2003","unstructured":"Dalhoff A, Thomson CJ. The art of fusion: from penams and cephems to penems. Chemotherapy. 2003, 49:105-20. 10.1159\/000070616","journal-title":"Chemotherapy"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.5.2.185","article-title":"Faropenem: review of a new oral penem","volume":"5","author":"Schurek KN","year":"2007","unstructured":"Schurek KN, Wiebe R, Karlowsky JA, Rubinstein E, Hoban DJ, Zhanel GG. Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther. 2007, 5:185-98. 10.1586\/14787210.5.2.185","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref11","article-title":"Penicillins and \u03b2-Lactam Inhibitors","author":"Chambers H","year":"2005","unstructured":"Chambers H. Penicillins and \u03b2-Lactam Inhibitors. Principles and Practice of Infectious Diseases. Mandell GL, Bennett JE, Dolin R (ed): Elsevier, Philadelphia, PA; 2005. 1:281-93."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000071141","article-title":"Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria","volume":"49","author":"Dalhoff A","year":"2003","unstructured":"Dalhoff A, Nasu T, Okamoto K. Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria. Chemotherapy. 2003, 49:172-83. 10.1159\/000071141","journal-title":"Chemotherapy"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.1964-1971.2001","article-title":"Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay","volume":"45","author":"Okamoto K","year":"2001","unstructured":"Okamoto K, Gotoh N, Nishino T. Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Antimicrob Agents Chemother. 2001, 45:1964-71. 10.1128\/AAC.45.7.1964-1971.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000072446","article-title":"Beta-lactamase stability of faropenem","volume":"49","author":"Dalhoff A","year":"2003","unstructured":"Dalhoff A, Nasu T, Okamoto K. Beta-lactamase stability of faropenem. Chemotherapy. 2003, 49:229-36. 10.1159\/000072446","journal-title":"Chemotherapy"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00310-08","article-title":"Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem","volume":"52","author":"Critchley IA","year":"2008","unstructured":"Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N. Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. Antimicrob Agents Chemother. 2008, 52:2639-43. 10.1128\/AAC.00310-08","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.11553\/antibiotics1968b.48.103","article-title":"Laboratory and clinical studies on SY5555 in pediatrics. (Article in Japanese)","volume":"48","author":"Iwai N","year":"1995","unstructured":"Iwai N, Nakamura H. Laboratory and clinical studies on SY5555 in pediatrics. (Article in Japanese). Jpn J Antibiot. 1995, 48:103-28. 10.11553\/antibiotics1968b.48.103","journal-title":"Jpn J Antibiot"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.11553\/antibiotics1968b.48.133","article-title":"Studies on SY5555 in the field of pediatrics","volume":"48","author":"Kitamura K","year":"1995","unstructured":"Kitamura K, Ihara T, Kamiya H, et al.. Studies on SY5555 in the field of pediatrics. Jpn J Antibiot. 1995, 48:133-9. 10.11553\/antibiotics1968b.48.133","journal-title":"Jpn J Antibiot"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.11553\/antibiotics1968b.48.71","article-title":"Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field. (Article in Japanese)","volume":"48","author":"Toyonaga Y","year":"1995","unstructured":"Toyonaga Y, Ishihara T, Tezuka T, et al.. Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field. (Article in Japanese). Jpn J Antibiot. 1995, 48:71-91. 10.11553\/antibiotics1968b.48.71","journal-title":"Jpn J Antibiot"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf155","article-title":"Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem","volume":"50","author":"Boswell FJ","year":"2002","unstructured":"Boswell FJ, Ashby JP, Andrews JM, Wise R. Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem. J Antimicrob Chemother. 2002, 50:525-32. 10.1093\/jac\/dkf155","journal-title":"J Antimicrob Chemother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.14.1497.31937","article-title":"Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem","volume":"23","author":"Hamilton-Miller JM","year":"2003","unstructured":"Hamilton-Miller JM. Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem. Pharmacotherapy. 2003, 23:1497-507. 10.1592\/phco.23.14.1497.31937","journal-title":"Pharmacotherapy"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/35.4.535","article-title":"Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria","volume":"35","author":"Cormican MG","year":"1995","unstructured":"Cormican MG, Jones RN. Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria. J Antimicrob Chemother. 1995, 35:535-9. 10.1093\/jac\/35.4.535","journal-title":"J Antimicrob Chemother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg263","article-title":"In vitro activity of faropenem compared with eight agents against fourteen Gram-positive and Gram-negative bacteria by time-kill","volume":"51","author":"Credito KL","year":"2003","unstructured":"Credito KL, Jacobs MR, Appelbaum PC. In vitro activity of faropenem compared with eight agents against fourteen Gram-positive and Gram-negative bacteria by time-kill. J Antimicrob Chemother. 2003, 51:1437-9. 10.1093\/jac\/dkg263","journal-title":"J Antimicrob Chemother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.3.415","article-title":"Pharmacodynamic properties of faropenem demonstrated by studies of time-kill kinetics and postantibiotic effect","volume":"39","author":"Boswell FJ","year":"1997","unstructured":"Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of faropenem demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother. 1997, 39:415-8. 10.1093\/jac\/39.3.415","journal-title":"J Antimicrob Chemother"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.11553\/antibiotics1968b.61.366","article-title":"Efficacy and safety of faropenem in pediatric patients with bacterial infectious diseases. (Article in Japanese)","volume":"61","author":"Yokota T","year":"2008","unstructured":"Yokota T, Azagami S, Abe T, et al.. Efficacy and safety of faropenem in pediatric patients with bacterial infectious diseases. (Article in Japanese). Jpn J Antibiot. 2008, 61:366-78. 10.11553\/antibiotics1968b.61.366","journal-title":"Jpn J Antibiot"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.11553\/antibiotics1968b.48.49","article-title":"Clinical studies on SY5555 in pediatric infections. (Article in Japanese)","volume":"48","author":"Niinou K","year":"1995","unstructured":"Niinou K, Sigeta M, Kuwahata K, et al.. Clinical studies on SY5555 in pediatric infections. (Article in Japanese). Jpn J Antibiot. 1995, 48:49-70. 10.11553\/antibiotics1968b.48.49","journal-title":"Jpn J Antibiot"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.11553\/antibiotics1968b.48.210","article-title":"A clinical evaluation of SY5555 in the treatment of pediatric infections","volume":"48","author":"Furukawa S","year":"1995","unstructured":"Furukawa S, Okada T. A clinical evaluation of SY5555 in the treatment of pediatric infections. Jpn J Antibiot. 1995, 48:210-9. 10.11553\/antibiotics1968b.48.210","journal-title":"Jpn J Antibiot"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.11553\/antibiotics1968b.48.191","article-title":"Bacteriological and clinical studies of SY5555 in pediatric field. (Article in Japanese)","volume":"48","author":"Nishimura T","year":"1995","unstructured":"Nishimura T, Sugita K, Aoki S, et al.. Bacteriological and clinical studies of SY5555 in pediatric field. (Article in Japanese). Jpn J Antibiot. 1995, 48:191-9. 10.11553\/antibiotics1968b.48.191","journal-title":"Jpn J Antibiot"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.11250\/chemotherapy1995.45.872","article-title":"Basic and clinical studies of faropenem in pediatric infection","volume":"45","author":"Fujii R","year":"1997","unstructured":"Fujii R, Abe T, Tajima T, et al.. Basic and clinical studies of faropenem in pediatric infection. Jpn J Chemother. 1997, 45:888-90. 10.11250\/chemotherapy1995.45.872","journal-title":"Jpn J Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/93593-role-of-faropenem-in-treatment-of-pediatric-infections-the-current-state-of-knowledge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:20Z","timestamp":1707507440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/93593-role-of-faropenem-in-treatment-of-pediatric-infections-the-current-state-of-knowledge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.24453","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,25]]}}}